Oslo, 18 February 2021 – Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.circio.com/en/capital-markets-day-2021/
Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.
The agenda will be as follows:
| Agenda & speakers | ||
| 2:30-2:40 PM | Welcome | Øystein Soug, CEO, Targovax |
| 2:40-3:25 PM | Anti-PD1 refractory melanoma | Alexander N. Shoushtari, MD |
| 3:25-3:45 PM | ONCOS-102 development program | Magnus Jäderberg, MD, CMO, Targovax |
| 5-minute break | ||
| 3:50-4:05 PM | Immune activation | Victor Levitsky, PhD CSO, Targovax |
| 4:05-4:15 PM | Preclinical pipeline update | Victor Levitsky, PhD, CSO, Targovax |
| 4:15-4:25 PM | 4Q update | Torbjørn Furuseth, MD, CFO, Targovax |
| 4:25 PM | Closing remarks | Øystein Soug, CEO, Targovax |
The presentations will be made available on the company´s website after
The presentations will be made available on the company´s website after the end of the meeting. Questions can be submitted through the webcast throughout the event.
Biography:
Dr. Alexander Shoushtari is a renowned expert in melanoma, with a research focus on checkpoint refractory melanomas. He is a Clinical Director and Assistant attending physician at Melanoma Services, Dept of Medicine, Memorial Sloan Kettering Cancer Center. Dr. Alexander Shoushtari is Principal investigator of several immunotherapy trials, including the ONCOS-102 phase I trial in CPI refractory advanced melanoma.
***
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz – LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.